Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer

Clin Colorectal Cancer. 2006 May;6(1):29-31. doi: 10.3816/CCC.2006.n.01.

Abstract

Monoclonal antibodies against the epidermal growth factor receptor have proven efficacy as monotherapy and in combination with chemotherapy in patients with metastatic colorectal cancer (CRC: mCRC). Initial clinical trials in CRC used the human-murine chimeric monoclonal antibody cetuximab. Ongoing studies are being conducted to evaluate the efficacy and safety of the fully human anti-epiderman growth factor receptor monoclonal antibody panitumumab. The results of a phase III trial which compared panitumumab as a single agent to best supportive care in patients with previously treated metastatic CRC have recently been reported Pantitumumab therapy resulted in a 46% reduction in the risk of tumor progression and a partial response rate of 8%. Rash was reported in 90% of patients with increased severity significantly correlated with improved medium overall survival (OS). Further clinical studies re ongoing and planned to test panitumumab in combination with chemotherapy in first-line therapy of advanced-stage CRC and adjuvant treatment of colon cancer.

Publication types

  • Clinical Trial, Phase III
  • Randomized Controlled Trial

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / secondary*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Colorectal Neoplasms / pathology*
  • Cross-Over Studies
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Middle Aged
  • Palliative Care
  • Panitumumab

Substances

  • Antibodies, Monoclonal
  • Panitumumab